한글목차

다사티닙 제제 시장 규모는 최근 현저한 성장을 보이고 있습니다. 2025년 15억 3,000만 달러에서 2026년에는 16억 3,000만 달러로, CAGR 6.3%로 확대될 전망입니다. 지난 수년간의 성장에는 백혈병에 대한 티로신 키나아제 억제제의 승인, 만성 골수성 백혈병 유병률 증가, 다사티닙의 내성 환자에서의 임상적 성공, 종양 치료 센터의 확대, 경구용 표적 치료제의 보급 등이 주요 요인으로 작용한 것으로 보입니다.

다사티닙 제제 시장 규모는 향후 몇 년간 견조한 성장이 전망됩니다. 2030년에는 20억 8,000만 달러에 달하고, CAGR은 6.3%가 될 전망입니다. 예측 기간의 성장 요인으로는 백혈병 환자 수 증가, 맞춤형 암 치료 수요 확대, 제네릭 암 치료제 보급 확대, 재택 암 치료 확대, 표적 치료제 개발 진전 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 표적항암제 사용 증가, 경구용 항암제 사용 확대, 다사티닙 제네릭 제품 수요 증가, 병용요법 접근법 확대, 경구용 제제의 환자 순응도 향상 등을 꼽을 수 있습니다.

만성 골수성 백혈병(CML)의 유병률 증가는 향후 몇 년 동안 다사티닙 시장의 성장을 견인할 것으로 예상됩니다. 만성 골수성 백혈병(CML)은 골수와 혈액에 영향을 미치는 암의 일종으로 비정상적인 백혈구의 통제할 수 없는 증식이 특징입니다. CML의 유병률 증가에는 환경 노출 증가와 생활습관 관련 위험요인이 영향을 미치고 있습니다. 다사티닙 의약품 시장은 백혈병 세포의 무제한 증식을 유발하는 BCR-ABL 티로신 키나아제 단백질을 표적으로 하여 질병 관리를 돕습니다. 예를 들어, 2023년 1월 미국 암 전문 보건 기관인 미국암협회(ACS)가 보고한 바에 따르면, 미국 내 CML 발병 건수는 2022년 8,860건에서 2023년 8,930건으로 증가하였다고 합니다. 그 결과, 만성 골수성 백혈병(CML)의 유병률 증가가 다사티닙 치료제 시장 확대를 촉진하고 있습니다.

다사티닙 치료제 시장에서 사업을 전개하고 있는 주요 기업들은 시장 접근성 확대, 보다 저렴한 치료 옵션 제공, 장기적인 암 치료가 필요한 환자들에 대한 공급 강화를 위해 제네릭 의약품 개발에 집중하고 있습니다. 제네릭 다사티닙 제제는 브랜드 의약품과 치료적으로 동등한 제제이며, 동일한 유효성분, 용량, 품질, 임상적 효능을 보다 저렴한 비용으로 제공합니다. 이러한 접근방식은 가격의 경제성을 실현하고, 경쟁을 촉진하며, 환자와 의료시스템의 경제적 부담을 줄일 수 있습니다. 예를 들어, 2024년 9월 캐나다에 본사를 둔 제약회사 아포텍스(Apotex)는 성인 및 소아 특정 백혈병 치료제로 미국 최초의 스플라이셀(다사티닙) 제네릭 의약품을 출시하였습니다. 이를 통해 고품질의 저비용 대안을 제공함으로써 치료 접근성을 개선하고, 다사티닙 치료제 시장 내 경쟁력 있는 가격 책정을 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Dasatinib drugs are a type of targeted therapy called tyrosine kinase inhibitors, mainly used to treat blood cancers, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). They function by inhibiting proteins that promote cancer cell growth, helping to slow the progression of the disease. This results in improved survival outcomes and more effective disease management.

The primary products in the dasatinib drugs market include tablets, oral suspension, and other forms. Dasatinib is mainly offered as tablets, providing patients with a convenient oral administration option. The drug is indicated for conditions such as chronic myeloid leukemia, acute lymphoblastic leukemia, and other diseases, with end users comprising hospitals, specialty clinics, and home healthcare providers.

Tariffs have affected the dasatinib drugs market by increasing the cost of imported active pharmaceutical ingredients and key synthesis intermediates used in oncology drug manufacturing. These impacts are most evident among oncology drug manufacturers and hospital supply chains, particularly in regions that depend on cross border pharmaceutical sourcing. Rising tariff related input costs have contributed to higher production expenses and modest increases in treatment pricing. This has influenced procurement planning and reimbursement considerations in cancer care settings. However, tariffs are also encouraging domestic api manufacturing, local production of oncology drugs, and greater regional supply chain resilience over the long term.

The dasatinib drugs market research report is one of a series of new reports from The Business Research Company that provides dasatinib drugs market statistics, including dasatinib drugs industry global market size, regional shares, competitors with a dasatinib drugs market share, detailed dasatinib drugs market segments, market trends and opportunities, and any further data you may need to thrive in the dasatinib drugs industry. This dasatinib drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dasatinib drugs market size has grown strongly in recent years. It will grow from $1.53 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to approval of tyrosine kinase inhibitors for leukemia, increasing prevalence of chronic myeloid leukemia, clinical success of dasatinib in resistant cases, expansion of oncology treatment centers, availability of oral targeted therapies.

The dasatinib drugs market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to growth in leukemia patient population, rising demand for personalized cancer treatment, increased penetration of generic oncology drugs, expansion of home-based cancer care, advancements in targeted drug development. Major trends in the forecast period include rising adoption of targeted cancer therapies, increasing use of oral oncology drugs, growing demand for generic dasatinib products, expansion of combination therapy approaches, improved patient adherence through oral formulations.

The rising prevalence of chronic myeloid leukemia (CML) is expected to drive the growth of the dasatinib drug market in the coming years. Chronic myeloid leukemia (CML) is a type of cancer affecting the bone marrow and blood, marked by the uncontrolled proliferation of abnormal white blood cells. The growing prevalence of CML is influenced by increased environmental exposures and lifestyle-related risk factors. The dasatinib drug market aids in disease management by targeting the BCR-ABL tyrosine kinase protein, which is responsible for the unchecked growth of leukemic cells. For example, in January 2023, the American Cancer Society (ACS), a US-based cancer-focused health organization, reported that CML cases in the United States rose to 8,930 in 2023, up from 8,860 cases in 2022. Consequently, the rising prevalence of chronic myeloid leukemia (CML) is fueling the expansion of the dasatinib drug market.

Major companies operating in the dasatinib drugs market are concentrating on developing generic versions to broaden market access, provide more affordable treatment options, and enhance availability for patients requiring long-term cancer therapy. Generic dasatinib medications are therapeutically equivalent formulations of the branded drug, delivering the same active ingredient, dosage, quality, and clinical effectiveness at a lower cost. This approach increases affordability, encourages competition, and reduces the financial burden on patients and healthcare systems. For example, in September 2024, Apotex Corp., a Canada-based pharmaceutical company, introduced the first generic version of Sprycel (dasatinib) in the United States for treating specific types of leukemia in adults and children, providing a high-quality, lower-cost alternative that improves treatment access and fosters competitive pricing within the dasatinib drugs market.

In January 2025, Handa Therapeutics, a US-based healthcare technology company, acquired PHYRAGO (dasatinib) tablets, an FDA-approved therapy for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia, from Nanocopoeia, LLC, for an undisclosed sum. Through this acquisition, Handa Therapeutics intends to enhance its oncology portfolio and broaden its presence in the chronic myeloid leukemia (CML) therapeutics market. Nanocopoeia, LLC, is a US-based biopharmaceutical firm that focuses on developing and manufacturing a specialized formulation of the dasatinib drug.

Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Sun Pharmaceutical Industries Limited, Hetero Drugs Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Lupin Limited, MSN Laboratories Pvt. Ltd., Hikma Pharmaceuticals plc, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP

North America was the largest region in the dasatinib drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dasatinib drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dasatinib drugs market consists of sales of sprycel and generic dasatinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dasatinib Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses dasatinib drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dasatinib drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dasatinib drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Tablets; Oral Suspension; Other Products
• 2) By Indication: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Other Indications
• 3) By End User: Hospitals; Specialty Clinics; Home Healthcare
• Subsegments:
• 1) By Tablets: 20 mg Tablets; 50 mg Tablets; 70 mg Tablets; 80 mg Tablets
• 2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension; 40 mg Or 5 mL Oral Suspension
• 3) By Other Products: Combination Therapies; Generic Dasatinib Products
• Companies Mentioned: Bristol-Myers Squibb Company; Teva Pharmaceutical Industries Ltd.; Sandoz Group AG; Sun Pharmaceutical Industries Limited; Hetero Drugs Limited; Aurobindo Pharma Limited; Dr. Reddy's Laboratories Limited; Intas Pharmaceuticals Ltd.; Cipla Limited; Lupin Limited; MSN Laboratories Pvt. Ltd.; Hikma Pharmaceuticals plc; Zhejiang Hisun Pharmaceutical Co. Ltd.; Biocon Limited; Alkem Laboratories Limited; Glenmark Pharmaceuticals Limited; Torrent Pharmaceuticals Limited; Alembic Pharmaceuticals Limited; Mylan N.V.; Manus Aktteva Biopharma LLP
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Dasatinib Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Dasatinib Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Dasatinib Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Dasatinib Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Artificial Intelligence & Autonomous Intelligence
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Targeted Cancer Therapies
  • 4.2.2 Increasing Use Of Oral Oncology Drugs
  • 4.2.3 Growing Demand For Generic Dasatinib Products
  • 4.2.4 Expansion Of Combination Therapy Approaches
  • 4.2.5 Improved Patient Adherence Through Oral Formulations

5. Dasatinib Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Oncology Clinics
• 5.3 Cancer Treatment Centers
• 5.4 Home Healthcare Providers
• 5.5 Research And Academic Institutions

6. Dasatinib Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Dasatinib Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Dasatinib Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Dasatinib Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Dasatinib Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Dasatinib Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Dasatinib Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Dasatinib Drugs Market Segmentation

• 9.1. Global Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Tablets, Oral Suspension, Other Products
• 9.2. Global Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications
• 9.3. Global Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Home Healthcare
• 9.4. Global Dasatinib Drugs Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 20 mg Tablets, 50 mg Tablets, 70 mg Tablets, 80 mg Tablets
• 9.5. Global Dasatinib Drugs Market, Sub-Segmentation Of Oral Suspension, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 20 mg Or 5 mL Oral Suspension, 40 mg Or 5 mL Oral Suspension
• 9.6. Global Dasatinib Drugs Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Combination Therapies, Generic Dasatinib Products

10. Dasatinib Drugs Market Regional And Country Analysis

• 10.1. Global Dasatinib Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Dasatinib Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Dasatinib Drugs Market

• 11.1. Asia-Pacific Dasatinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Dasatinib Drugs Market

• 12.1. China Dasatinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Dasatinib Drugs Market

• 13.1. India Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Dasatinib Drugs Market

• 14.1. Japan Dasatinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Dasatinib Drugs Market

• 15.1. Australia Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Dasatinib Drugs Market

• 16.1. Indonesia Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Dasatinib Drugs Market

• 17.1. South Korea Dasatinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Dasatinib Drugs Market

• 18.1. Taiwan Dasatinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Dasatinib Drugs Market

• 19.1. South East Asia Dasatinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Dasatinib Drugs Market

• 20.1. Western Europe Dasatinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Dasatinib Drugs Market

• 21.1. UK Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Dasatinib Drugs Market

• 22.1. Germany Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Dasatinib Drugs Market

• 23.1. France Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Dasatinib Drugs Market

• 24.1. Italy Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Dasatinib Drugs Market

• 25.1. Spain Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Dasatinib Drugs Market

• 26.1. Eastern Europe Dasatinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Dasatinib Drugs Market

• 27.1. Russia Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Dasatinib Drugs Market

• 28.1. North America Dasatinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Dasatinib Drugs Market

• 29.1. USA Dasatinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Dasatinib Drugs Market

• 30.1. Canada Dasatinib Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Dasatinib Drugs Market

• 31.1. South America Dasatinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Dasatinib Drugs Market

• 32.1. Brazil Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Dasatinib Drugs Market

• 33.1. Middle East Dasatinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Dasatinib Drugs Market

• 34.1. Africa Dasatinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Dasatinib Drugs Market, Segmentation By Product Type, Segmentation By Indication, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Dasatinib Drugs Market Regulatory and Investment Landscape

36. Dasatinib Drugs Market Competitive Landscape And Company Profiles

• 36.1. Dasatinib Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Dasatinib Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Dasatinib Drugs Market Company Profiles
  • 36.3.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Hetero Drugs Limited Overview, Products and Services, Strategy and Financial Analysis

37. Dasatinib Drugs Market Other Major And Innovative Companies

• Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Lupin Limited, MSN Laboratories Pvt. Ltd., Hikma Pharmaceuticals plc, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP

38. Global Dasatinib Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Dasatinib Drugs Market

40. Dasatinib Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Dasatinib Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Dasatinib Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Dasatinib Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer